Suppression of Ser/Thr Phosphatase 4 (PP4C/PPP4C) Mimics a Novel Post-Mitotic Action of Fostriecin, Producing Mitotic Slippage Followed by Tetraploid Cell Death

Benjamin Theobald, Kathy Bonness, Alla Musiyenko, Joel F. Andrews, Gudrun Urban, Xizhong Huang, Nicholas M. Dean, and Richard E. Honkanen

Abstract

Fostriecin is a natural product purified from Streptomyces extracts with antitumor activity sufficient to warrant human clinical trials. Unfortunately, difficulties associated with supply and stable drug formulation stalled further development. At a molecular level, fostriecin is known to act as a catalytic inhibitor of four PPP-family phosphatases, and reports describing the design of molecules in this class suggest derivatives targeting enzymes within the fostriecin-sensitive subfamily can be successful. However, it is not clear if the tumor-selective cytotoxicity of fostriecin results from the inhibition of a specific phosphatase, multiple phosphatases, or a limited subset of fostriecin-sensitive phosphatases. How the inhibition of sensitive phosphatases contributes to tumor-selective cytotoxicity is also not clear. Here, high-content time-lapse imaging of live cells revealed novel insight into the cellular actions of fostriecin, showing that fostriecin-induced apoptosis is not simply induced following a sustained mitotic arrest. Rather, apoptosis occurred in an apparent second interphase produced when tetraploid cells undergo mitotic slippage. Comparison of the actions of fostriecin and antisense-oligonucleotides specifically targeting human fostriecin-sensitive phosphatases revealed that the suppression of PP4C alone is sufficient to mimic many actions of fostriecin. Importantly, targeted suppression of PP4C induced apoptosis, with death occurring in tetraploid cells following mitotic slippage. This effect was not observed following the suppression of PP1C, PP2AC, or PP5C. These data clarify PP4C as a fostriecin-sensitive phosphatase and demonstrate that the suppression of PP4C triggers mitotic slippage/apoptosis.

Implications: Future development of fostriecin class inhibitors should consider PP4C as a potentially important target.

Introduction

Fostriecin and structurally related phosphate monoesters produced by Streptomyces sp. (i.e., cytostatin) display cytotoxicity and antitumor activity (for review, see refs. 1, 2). Cytostatin has potent cytotoxic activity toward melanoma and leukemia cell lines and inhibits B16 melanoma lung metastasis in a mouse model of cancer progression (3). The antitumor activity of fostriecin (also called

PD-110,161, CI-920 or NSC-339638) has been evaluated extensively (4); for review, see refs. 1, 5). Fostriecin shows potent cytotoxicity against a number of cancer cell lines and marked antitumor activity in animals (for review, see refs. 1, 5, 6). To evaluate its potential for use as a novel antitumor agent in humans, fostriecin entered human clinical trials (7, 8). Although limited, the data obtained from the phase I trials indicate that plasma levels of fostriecin associated with antitumor activity in animals (9) can be achieved in humans (7, 8). Unfortunately, further development has been suspended for nearly a decade, due to early controversies regarding its mechanism of action, problems associated with the supply of fostriecin from natural sources, and difficulty associated with stable drug formulation (8).

Now methods for synthesis are known, and the molecular targets of fostriecin are becoming clear. Fostriecin (1, 10–13), structurally related natural products [e.g. cytostatin (14, 15) phospholine, leustroducsin, and phoslactomycins (1, 16, 17)] and designed analogs used to explore the structure–function properties and mechanisms of action of molecules in the class (11, 12, 15), all inhibit the catalytic activity of a subset of PPP family serine/threonine protein

Authors' Affiliations: *Department of Biochemistry and Molecular Biology, **Mitchell Cancer Research Institute, University of South Alabama College of Medicine, Mobile, Alabama; and *Department of Pharmacology, ISIS Pharmaceuticals, Carlsbad, California

Note: Supplementary data for this article are available at Molecular Cancer Research Online (http://mcr.aacrjournals.org/).

B. Theobald and K. Bonness contributed equally to this work.

Corresponding Author: Richard E. Honkanen, Department of Biochemistry and Molecular Biology, MSB 2362, University of South Alabama, Mobile, AL 36688. Phone: 251 460-6859; Fax: 251 460-6850; E-mail: rhonkanen@southalabama.edu

doi: 10.1158/1541-7786.MCR-13-0032

©2013 American Association for Cancer Research.

www.aacrjournals.org
phosphatases. Fostriecin is a potent inhibitor of PP2A/C (IC50 ~0.2 nmol/L (10, 11, 13)), a strong inhibitor of PP4C (IC50 ~ 4 nmol/L (18)), and a weak inhibitor of PP1C and PP5C (IC50, 72 and 60 μmol/L, respectively; refs. 10, 11). Structural studies have revealed that the fostriecin-sensitive phosphatases share a common catalytic mechanism (19). Structure–activity relationship (SAR) studies indicate that selectivity for PP2A/C is derived from the interaction of C3 with a noncatalytic cysteine of PP2A/C (C269), which is not conserved in PP1C or PP5 (12, 19), and the predicted covalent adduct with PP2A/C has been shown using a biotin-labeled derivative (20). The B12–B13 loops of PP4 and PP6 contain a homologous cysteine, suggesting it serves as a commonality for strong inhibition (11, 12, 19). However, to our knowledge, these predicted actions on PP4C and PP6C have not been tested experimentally. Fostriecin has no apparent effects on PP2B (calcineurin), PP7, or PP2 family phosphatases (for review, see refs. 1, 6). SAR studies have also provided insight into other features needed for potency, selectivity, and stability, sparking renewed interest in the development of compounds in this class (11, 12, 15, 21, 22).

The basis for the antitumor activity of fostriecin is not clear. At the cellular level, fostriecin enters cells via folic acid transporters (23, 24), and at concentrations sufficient to inhibit PP1C, PP2A/C, PP4C and PP5C (>125 μmol/L), it kills both tumor and normal cells (13). Many of the toxic effects are cell-cycle–independent and similar to the toxic actions produced by other natural compounds that act as strong, nonselective inhibitors of PP1C, PP2A/C, PP4C, and PP5 (e.g., microcystin-LR and calyculin A). Nonetheless, similar to early observations made with paclitaxel (taxol), preclinical studies indicate that fostriecin has antitumor activity in animals at nontoxic concentrations (<50 μmol/L; refs. 5, 8, 9, 25). At ≤50 μmol/L, fostriecin induces an apoptotic response in many types of cancer cells (26). However, fostriecin-induced apoptosis is slow, requiring more than 24 to 48 hours, and death is preceded by the accumulation of cells with 4N DNA (13, 27, 28). Cantharidin, a less selective natural inhibitor of PP1–PP5 that also has cytotoxic and antitumor activity, produces a similar accumulation of cells with 4N DNA before the onset of apoptosis. This suggested the antitumor activity of both compounds could arise from their ability to prolong mitosis, triggering mitotic/spindle checkpoint control mechanisms (29).

To help clarify the relationship between tumor-selective cytotoxicity and phosphatase inhibition, we developed 2′-O-methyl phosphorothioate deoxyligonucleotides capable of specifically suppressing the expression of fostriecin-sensitive phosphatases (29–31). Previous studies have shown that, like fostriecin, the suppression of PP2AC, but not PP2ACβ, PP1Cγ1, or PP5C, induces a prolonged mitotic arrest (29). Further investigations revealed that PP2AC forms a complex with a kinetochore-associated protein (Sgo1/MEI-S332) during metaphase (32–35). The PP2AC/Sgo1/kinetochore complex protects cohesin-residing at the kinetochore from phosphorylation-mediated dissociation before the onset of anaphase (32–35). Thus, when PP2AC is suppressed, the activation of mitotic kinases (i.e., Plk1, Aurora A/B) results in the premature dissociation of sister chromatids. This prevents biorientation (the attachment of duplicated chromatids via their kinetochores to opposite poles within a microtubule-based mitotic spindle), which activates or maintains the spindle assembly checkpoint controls that prevent progression into anaphase (32–35). These observations lead to the widely accepted hypothesis that fostriecin-induced apoptosis was simply due to its ability to produce a prolonged mitotic arrest via the inhibition of PP2AC. However, the prolonged mitotic arrest induced by the suppression of PP2AC alone did not trigger apoptosis (29), prompting us to re-examine the actions of fostriecin. Here, high-content time lapse imaging of live cells reveals that fostriecin-induced apoptosis is not simply produced by the induction of a prolonged mitosis. Rather, death occurred in tetraploid cells produced following mitotic slippage. This effect was mimicked by antisense targeting PP4C (but not by antisense targeting PP1C, PP2AC, or PP5C), revealing a novel role for PP4C during mitotic progression.

Materials and Methods
Cell culture
A549 and HeLa cells were obtained from American Type Culture Collection. A well-characterized stable HeLa cell line constitutively expressing a histone 2B-GFP fusion protein (H2B-GFP; HeLa-H2B-GFP cells) was a generous gift from Dr. Kevin Sullivan (36). Both cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS and l-glutamine (4.0 mmol/L) at 37°C in 5% CO2.

Chemicals
Fostriecin was synthesized as described previously (11).

Oligonucleotide synthesis and assay for oligonucleotide inhibition of PP2ACα or PP4C expression
Phosphorothioate deoxyligonucleotides and 2′-O-methyl phosphorothioate deoxyligonucleotides were synthesized and purified as described previously (37). The indicated cells were plated in 60-mm dishes and cultured in DMEM containing 10% FBS. When about 50% confluent, the cells were treated with oligonucleotides as previously described (30, 38). Because phosphorothioate oligonucleotides act through RNAase H–dependent mRNA cleavage mechanism in cells, the ability of each oligonucleotide to specifically inhibit the expression of PP4C was initially determined by Northern blot analysis probing for levels of PP4C mRNA (39). Antisense oligonucleotides targeting PP1C (γ1), both isoforms of PP2Ac (PP2ACα, PP2ACβ) and PP5 have been developed and characterized previously (29–31, 40). The characterization of antisense oligonucleotides targeting PP4C is provided in Supplementary Fig. S1.
Suppression of PP4C Triggers Mitotic Slippage and Apoptosis

Immunoblotting of PP2A, PP4C, PP5, and PP6

Western blot analysis was conducted as described previously using polyclonal rabbit antibodies generated against a synthetic 15-aa peptide identical to unique regions of PP2A, PP4C, PP5, and PP6 (29–31, 41). The antibody targeting PP2A does not discriminate between PP2Aα and PP2Aβ (29).

Caspase-3 activity

Caspase-3 activity was measured using a CASP3C colorimetric assay (optical density at 405 nm) according to the instructions provided by the manufacturer (Sigma). All experiments were repeated at least 3 times.

Flow cytometry

A549 cells were harvested, stained with propidium iodide (PI), and DNA content flow cytometry was conducted as described previously (29).

Live cell imaging and time lapse video microscopy

HeLa-H2B-GFP cells were cultured in 60-mm dishes and incubated at 37°C in 5% CO2 using a Neuve live cell chamber fitted into an Eclipse Nikon TE 2000-U microscope (Nikon Instruments Inc.). Image acquisition was achieved using a COOLSNAP ES monochrome camera and processed using Elements (Nikon) and MetaMorph Premier software (Universal Imaging).

Analysis of live cell imaging

To study mitotic progression, we used live cell imaging in combination with time lapse video microscopy using an established HeLa cell line (HeLa-H2B-GFP) expressing histone 2B fused with GFP (29, 32, 36). Here, both fluorescent and differential interference contrast (DIC) images of live cell cultures were taken at timed intervals (every 2–5 minutes) for the duration of experiments lasting from 12 to 72 hours. Short exposure times and neutral density filters were used to minimize UV exposure to cells, and control experiments using solvent or mismatched antisense oligonucleotides were carried out to ensure the observations made were not due to UV damage produced during fluorescent imaging. In each experiment, images of more than 300 cells can be analyzed at every time point for the duration of the experiment. H2B-GFP expression in interphase cells is dispersed throughout the nucleus, and chromosome condensation (marking the onset of prophase) is easily distinguished from dispersed nuclear fluorescence of interphase cells (Fig. 1A). Metaphase alignment of sister chromatids, mitotic defects, and sister chromatid separation (indicating the onset of anaphase) can also be easily distinguished. The nuclear envelope breakdown and the onset of cytokinesis are easily detected in corresponding DIC images. Therefore, analysis of sequential images allows for quantitative assessment of the time needed for cell-cycle progression from prophase to metaphase, anaphase, and cytokinesis. Analysis of live cell images also allows us to provide a detailed description of mitotic defects induced by the various treatments and to quantitate the frequency that these defects are produced.

Results

Quantitation of cell-cycle progression in controls

To further characterize the cellular effects of fostriecin, live cell imaging, in combination with time lapse video microscopy, was used using a HeLa cell line that stably expresses H2B fused with GFP (HeLa-H2B-GFP). This stable cell line is widely used because it allows high-resolution imaging of chromosomes without compromising nuclear or chromosomal structures (29, 32, 36), and it has proven useful as a powerful tool to study agents that affect chromosome condensation, metaphase plate alignment of sister chromatids, and mitotic progression into anaphase (29, 32, 36). In each experiment, images of about 300 to 500 live cells were taken at timed intervals (generally every 5 minutes) for 24 to 72 hours, as indicated. Individual images were then examined and analyzed with the aid of advanced imaging software (Elements and Metamorph). This procedure allows us to simultaneously assess several aspects of cell-cycle progression in about 50 to 300 individual cells per experiment. Then, following the fate of each cell, the duration required for progression from nuclear envelope break down (NEBD) to (i) chromosome alignment at the metaphase plate, (ii) the onset of anaphase, (iii) chromosome decondensation, (iv) cleavage furrow formation, and (v) cytokinesis was quantified. When abnormal behaviors were observed, the time of onset (relative to NEBD) and the ensuing fate of the cells were noted.

Progression through mitosis in control cells is illustrated in Fig. 1A. The data shown are typical of cell populations for more than 10 experiments, in which 50 to 100 mitotic cells are analyzed in each experiment. Quantitation of the data revealed that in untreated or solvent treated controls progression from NEBD (designated as 0 minutes) to chromosome decondensation and cytokinesis requires 1.3 ± 0.82 (mean ± SD; n = 300) hours (Fig. 2A). During this time, chromosome alignment at the metaphase plate (indicated with an asterisk) is observed about 20 minutes after NEBD in >97% ± 3% (mean ± SD) of the cells scored (n = 500). Separation of sister chromatids, indicating the onset of anaphase, occurs 49 ± 25 minutes thereafter (mean ± SD; n = 300) and is not observed until all of the chromosomes are aligned. In 96% of the cells analyzed, chromosome decondensation and cytokinesis occur <2.5 hours after the onset of NEBD. A delay during mitosis (defined as cells with condensed chromosomes that fail to proceed into anaphase in <2.5 hours) is rarely observed in untreated or solvent controls (<4%, n = 300) and is therefore considered an indication of "mitotic arrest."

Fostriecin prolongs mitosis and prevents cytokinesis

Fostriecin is known to induce apoptosis, and previous studies using fluorescence-activated cell-sorting (FACS) analysis have shown that before death fostriecin produces a dose-dependent accumulation of cells with 4N DNA (27). Consistent with previous studies, in the HeLa-H2B-GFP...
Figure 1. Localization of H2B-GFP protein in HeLa cells. Fluorescent and corresponding DIC microscopic images of selected HeLa-H2B-GFP cells representing the typical behavior of the populations are shown at various phases of the cell cycle. A, representative images selected from time lapse live cell imaging of control cells typical of: interphase at the start of recording (i), the start of mitotic entry (set at 0 minutes), prometaphase (14 minutes), metaphase (45 minutes), anaphase (1.2–1.4 hours), chromosome decondensation (2.2 hours), and after the completion of cytokinesis (4.1 hours). Elapsed time from the start of mitotic entry is indicated below image pairs. B, images showing selected cells that represent the typical behavior of populations after treatment with 50 μmol/L fostriecin. No effects were observed before entry into mitosis (0 minutes). During a prolonged mitosis, condensed chromosomes fail to align properly at the metaphase plate (45 minutes; 4.6 hours). Subsequently, chromosomes segregated into unequal clusters (5.3 hours) and undergo decondensation (5.8 hours). During this period, more than one furrow appears (5.3, 5.8, and 7.7 hours). Then, the furrows undergo regression (shown here at 10.9 hours). C, images showing selected cells that represent the typical behavior of populations after treatment with antisense oligonucleotides targeting PP4C. H2B-GFP expressing HeLa cells were treated with 400 nmol/L ISIS 134947. After 24 hours, time lapse imaging studies were conducted for 48 hours as above. The similarity to the effects produced by fostriecin is striking: PP4C-AS interferes with the integrity of the metaphase plate (55 minutes) prolongs mitosis and allows cleavage furrow regression following mitotic slippage (shown at 18.2 hours). The data shown are representative of more than 4 separate experiments in which 50 to 100 mitotic cells were scored in each experiment. Bars under figure pairs are colored to illustrate images representing various stages of cell-cycle progression and are color matched to the quantitative data shown in Fig. 2. D, concentration-dependent increase in...
model, fostriecin (<50 µmol/L) produced no notable effects on cell-cycle progression before NEBD (Fig. 1B; designated as 0 minutes). Following chromosome condensation fostriecin prevents the proper alignment of sister chromatids at the metaphase plate (indicated at 45 minutes and 4.6 hours by arrows). Cells that do not achieve metaphase alignment arrest and do not progress into anaphase. Dose–response studies revealed a concentration-dependent increase in the frequency of cells with aberrant metaphase alignment, with maximal efficacy achieved with 50 µmol/L fostriecin (Fig. 1D). Quantification of the data revealed that fostriecin prolongs mitosis (5.4 ± 0.25 hours; mean ± SE); compare red bars shown in Fig. 2A with Fig. 2B; Fig. 2E]. During this period, the arrested cells remain rounded in appearance and the chromosomes remain condensed. The sister chromatids that do align at the metaphase plate do not separate, and the chromosomes that fail to align move in an unorganized manner. The fostriecin-arrested cells then progress into an aberrant form of anaphase. At the onset of “anaphase,” most fostriecin-treated cells attempt chromosome separation in a tri- or polypolar manner, which is associated with furrow ingression at 3 or more sites (shown at 5.3 hours in Fig. 1B). In these cells, aberrant furrow ingression does not result in abscission. Rather, after a delay the furrows regress, producing a single tetraploid cell. Some cells reform 3 or more nuclei that are unequal in size (shown at 10.9 hours). Chromosome decondensation occurs before regression, and with time, the tetraploid cells become apoptotic. By 48 hours, 50 µmol/L fostriecin killed more than 98% of the cells, and the IC50 for 72-hour cytotoxic activity of fostriecin is about 5 to 7 µmol/L (11, 17, 25). Only a small percentage (<4%) of the cells treated with 50 µmol/L fostriecin become apoptotic prior to the completion of mitosis (defined here as chromosome decondensation). Rather, in the majority of fostriecin-treated cells, death occurred several hours after furrow regression occurred (Fig. 2B and D; black bars). The occasional cell that eventually achieves metaphase alignment was not killed and appeared to progress normally into anaphase. As reported previously for other cell types (13, 27), polyplody above 4N was not observed in fostriecin-treated cells.

Suppression of PP4C prolongs mitosis and induces furrow regression before death

The concentration of fostriecin that altered mitotic progression is sufficient to completely inhibit the activity of PP2AC and PP4C, and the suppression of PP2AC did not produce furrow regression or tetraploid cells (29). Therefore, we developed antisense that specifically suppressed PP4C (Supplementary Fig. S1). Antisense oligonucleotides targeting PP4C had no effect on the expression of PP2AC, PP5 or PP6C, and the level of these structurally related phosphatases do not increase to compensate for the lack of PP4C (Fig. 3A). In the HeLa-H2B-GFP cell model, as observed in other cell lines, following treatment with antisense oligonucleotides targeting PP4C (PP4C-AS) >30 hours was required for PP4C protein levels to become maximally suppressed. Before about 50% suppression (~24 hours after treatment), cell division occurs normally. When PP4C levels are suppressed, PP4C-AS elicits a response that is strikingly similar to the response produced by fostriecin (compare Fig. 1B and C). First, the suppression of PP4C produced no apparent differences from controls before NEBD. Second, treatment with 400 nmol/L ISIS 134947 prolonged mitotic progression in about 60% of the cells (4.33 ± 0.47 hour; mean ± SE by Fig. 2) compared to less than 4% in cells treated MM controls. During this time, similar to the actions of fostriecin, cells arrested by PP4C-AS remain rounded in appearance and contained condensed chromosomes that fail to align properly at the metaphase plate (shown in Fig. 1C at 55 minutes and 2.5 hours). After a prolonged mitosis, multiple furrows initiate in the PP4-AS–treated cells (shown at 15 hours). With time, the furrows regress and chromosomes undergo decondensation, resulting in a single tetraploid cell (shown at 18.2 hours). However, it should be noted that when compared with fostriecin, both the average duration of mitosis and the time following furrow regression and proceeding apoptosis was highly variable in cells treated with PP4C-AS (compare bar length in Fig. 2B and C). This difference may reflect difficulties associated with the uniform delivery of antisense oligonucleotides to cell in culture or may reflect the combined inhibition of both PP2AC and PP4C in the fostriecin-treated cells. Additional data comparing the actions of fostriecin, PP4C-AS and PP2AC-AS is provided in Supplementary Figs. S2 and S3.

Suppression of PP4C expression induces apoptosis in the absence of cellular stress

Initial dose–response studies (Fig. 1E; Supplementary Fig. S1) revealed that the suppression of PP4C kills HeLa cells in culture after 72 hours (similar effects were observed in other lines of human cells). To determine whether death induced by antisense oligonucleotides targeting PP4C is due to apoptosis, cells treated with ISIS 14376 or ISIS 134947 were examined. Light microscopic examination of dying cells revealed classic signs of apoptosis (i.e., membrane blebbing and condensed fragmented DNA visualized by DAPI staining). Electron microscopic analysis revealed
numerous cells with homogenous condensation of chromatin contained in one side or the periphery of the nucleus in cells treated with antisense targeting PP4C, which is a hallmark characteristic of apoptosis (Fig. 3E). Analysis of more than 100 cells 48 hours after treatment revealed condensed chromatin and other characteristics of apoptosis in 4% ± 1% of the cells treated with lipofectin alone, 4% ± 2% of the cells treated with MM control oligonucleotides (500 nmol/L), 59% ± 3% of the cells treated with PP4C-AS at 300 nmol/L, and 75% ± 8% of the cells treated PP4C-AS at 400 nmol/L. Antisense oligonucleotides targeting PP4 also produced a dose-dependent increase in caspase-3 activity (Fig. 3C). FACS analysis using an Annexin V/FITC–labeled antibody also revealed an increase in apoptosis when PP4C expression was suppressed (data not shown). These studies indicate that antisense oligonucleotides capable of suppressing the expression of PP4C induce cell death via the induction of apoptosis.
Figure 3. Effects of antisense oligodeoxynucleotides targeting PP4C. A, target-specific inhibition of PP4C protein levels. Cells were treated with the either antisense oligonucleotides targeting PP4C (ISIS 134947 illustrated) or mismatch control oligonucleotides (MM; ISIS 131370 or ISIS 131371). Protein extracts were prepared at the times indicated and analyzed for structurally related phosphatases (PP2AC, PP4C, PP5, and PP6C) by Western blot analysis as described in Materials and Methods [the antibody for PP2AC recognizes both the α and β isoforms of PP2AC (29)]. B, dose-dependent suppression of PP4C mRNA levels by ISIS 134947 in HeLa cells. To ensure the uptake and efficacy of antisense oligonucleotides, for each experiment, replicate plates were treated with the oligonucleotides indicated and processed for Northern blot analysis after 24 hours, as described in Supplementary Fig. S1 and Supplementary Methods. Representative data obtained using ISIS 134947 and MM (ISIS 131371) are shown. C, caspase-3 activity. A549 cells were treated with nothing (1), lipofectin (lipid control; 2), 10 nmol/L TNF-α (positive control; 3), 10 nmol/L okadaic acid (OA; second positive control; 4), or the indicated concentration of ISIS 14376 (PP4C-AS; 5, 6, 7). After 36 hours, cells were harvested and caspase-3 activity was measured as described in Materials and Methods. The data is plotted as the mean OD405 ± SE from 3 replicate plates and is representative of 3 separate experiments. D and E, representative electron micrographs of A549 cell populations after treatment with MM (control) or antisense oligonucleotides (ISIS 14376) targeting PP4C. After treatment (48 hours), cells were harvested, fixed, stained, and then viewed by electron microscopy using standard protocols. Controls (D) have an intact membrane, organelles, and normal nuclear morphology. ISIS 14376-treated cells (E) show homogeneous chromatin condensation within the nucleus (arrow), membrane blebbing and other characteristics common to apoptotic cells.
Suppression of PP4C is associated with aberrant mitotic spindles

To explore mechanisms by which PP4C-AS may prolong mitosis, we examined the effects of ISIS 134947 on microtubule behavior. Immunostaining with fluorescent-tagged anti-α-tubulin antibodies revealed that PP4C-AS has no apparent affect on microtubules in nondividing cells (Supplementary Fig. S4), whereas in mitotic cells, marked differences were observed between the mismatch control and PP4C-AS treatment. At mitosis, more than 98% of the control cells contain a typical array of anti-parallel microtubules characteristic of a normal bipolar mitotic spindle. In contrast, in PP4C-AS–treated cells, the spindle apparatus was aberrant, often composed of multiple "poles" (Fig. 4; indicated by arrows). On the basis of fluorescent immunostaining of fixed mitotic cells, it appears that PP4C-AS does not prevent the polymerization of microtubule structures in general. Rather, PP4C-AS disrupts the organization of the spindles.

Discussion

Microtubule binding drugs that disrupt mitotic progression (e.g., Vinca alkaloids and taxanes) have shown efficacy in the treatment of different types of cancer. Accordingly, intense efforts have been devoted to further the understanding of how cancer cells responded to known antimitotic

![Figure 4. Mitotic abnormalities associated with the suppression of PP4C. Representative confocal microscopic images of serial Z sections through a HeLa cell treated with antisense targeting PP4C. Cells were treated with 400 nmo/L ISIS 134947 and fixed on coverslips 30 hours later. A, microtubules (red) were then visualized by immunofluorescence following treatment with anti-α-tubulin and Alexa Fluor 594–labeled antibodies as described in Materials and Methods. B, DNA (blue) was visualized by staining with Hoechst 33342. C, computer-assisted merge of images A and B. Similar results were obtained with >3 independent experiments.]
drugs and to the development of agents that perturb mitotic progression via other, less toxic mechanisms. Indeed, agents targeting mitotic kinases [i.e., Polo-like kinase-1 (Plk1) and Aurora kinases] and microtubule-associated motor proteins (e.g., Eg5/Kinesin-5/KIF11 and CENP-E) are already in pre- or early clinical development. The studies described here add support to the hypothesis that the inhibition of fostriecin-sensitive phosphatases can also disrupt normal mitotic progression (Fig 1) without directly targeting microtubules, mitotic kinases, or motor proteins (10, 27). Our data also provide new insight into the cytotoxic actions of fostriecin and reveal, for the first time, that the suppression of a little-studied fostriecin-sensitive phosphatase (PP4C) is sufficient to prolong mitosis, alter cleavage furrow position/ingression, and induce apoptosis in the tetraploid cells produced following mitotic slippage.

Fostriecin is known to act as a strong inhibitor of PP2AC (10–12, 27), and fostriecin induces the accumulation of cells with 4N DNA that have aberrant mitotic spindles before the onset of apoptosis (10, 13, 27). Therefore, when studies of PP2AC action during mitotic progression revealed that PP2AC (in a complex with PR61/B and Sgo1 at the kinetochore) functions to protect centromeric cohesion from phosphorylation-mediated dissociation by the activation of mitotic kinases (i.e., Plk-1 or Aurora B; refs. 32, 33, 35), a simple hypothesis for the antitumor activity of fostriecin emerged. That is, the inhibition of PP2AC may allow the premature dissociation of centromere cohesion (32–35), which prevents biorientation and triggers/maintains mitotic spindle assembly checkpoint controls. Studies with antisense oligonucleotides targeting PP2AC support this hypothesis, in the respect that the specific suppression of PP2ACα is sufficient to arrest cells in mitosis, and the PP2AC-AS–arrested cells have lagging chromosomes that failed to align at the metaphase plate (29). Nonetheless, PP2AC can dephosphorylate a number of cyclin B–Cdk1 substrates (42, 43), suggesting that the inhibition of PP2AC could also prolong mitosis via numerous other mechanisms.

A key novel observation reported here is that although fostriecin treatment does prolong mitosis, apoptosis only occurs rarely during mitotic arrest (Figs 1 and 2). This argues that fostriecin does not kill cells by simply prolonging mitosis. Further characterization revealed that the fostriecin-treated cells exit mitosis (defined here as chromosome decondensation) but then fail to complete cytokinesis. Death then occurs after mitotic slippage in the tetraploid cells that are produced, during what appears to be a second interphase. These novel actions of fostriecin are not observed following the suppression of PP1Cγ1, PP2ACα, PP2ACβ, or PP5 (29–31) but are faithfully mimicked by the suppression of PP4C (Figs 1C and 2C).

Careful examination of the data reveals that there is great variation in the timing of cell death after treatment with fostriecin or antisense targeting PP4C. In general the actions of fostriecin were more uniform, which may reflect difficulties associated with various aspects of using antisense oligonucleotides in cultured cells (44) or differences produced by the rapid inhibition of PP4C activity by fostriecin compared with the gradual loss of PP4C protein following treatment with PP4-AS. Nonetheless, after treatment with either fostriecin or PP4-AS, we observed no clear correlation between the duration of mitotic delay and cell fate, suggesting that in this cell model, the time a cell spends in mitosis does not dictate whether it dies in mitosis or slips from mitotic arrest and dies later after cleavage furrow regression.

Studies of PP4C function in human cells have revealed that it plays an important role in the recovery of cell-cycle progression after DNA damage–mediated S-phase arrest (45), which was not addressed by our experiments. However, investigations of PP4C function in lower organisms may provide insight into some of the other affects produced by antisense oligonucleotides targeting PP4C in HeLa cells. In Drosophila embryos, the PP4C ortholog (91% identical to human PP4C) is required for the organization of microtubules at the centrosomes (18), and siRNA-mediated suppression in Drosophila affects polar division in neurons (46). The association of PP4C at the mitotic centrosomes has also been observed in higher organisms and is required for proper centrosome organization of microtubules (47, 48). Our studies show that the mitotic spindles in the PP4C-AS–treated cells are aberrant (Fig 4), whereas the microtubules in nonmitotic cells appeared normal (Supplementary Fig. S4). Although we cannot rule out the possibility that PP4C plays an independent and nonredundant role to PP2AC in the regulation of centromeric cohesion, the appearance of misaligned and Y-shaped metaphase alignment of sister chromatids, produced by PP4C-AS or fostriecin (but not PP2AC-AS), would be an expected consequence of agents that disrupt normal microtubule attachment at the centrosomes. Presumably disruption of centrosome/microtubule interactions would also interfere with biorentiation and prolong mitosis, which was observed after treatment with antisense specifically targeting PP4C.

Studies into the molecular mechanisms associated with cytokinetic abscission and signaling mechanism by which failures in cytokinesis can lead to regression and tetraploidy suggest reversible phosphorylation plays many regulatory roles. For example, in HeLa cells, chromosome bridges sustain Aurora B activity, and Aurora B has been shown to protect missegregating cells against cleavage furrow regression via a mechanism in which Aurora B–mediated phosphorylation of Mklp1 stabilizes Mklp1 at the intracellular canal (49). Chemical genetic studies of Plk1 function during mitosis indicate that the partial suppression of Plk1 can also result in cleavage furrow regression, leading to the formation of tetraploid cells (50). Phosphorylation at specific sites has been shown to activate Aurora B (Thr-232), Mklp1 (Ser 911), and Plk1 (Thr-210). However, our data are not consistent with PP4C acting to directly dephosphorylate key activating sites on these kinases because the inhibition of Aurora B, Plk1, or PP4C lead to furrow regression and the formation of tetraploid cells. Our data appears to be consistent with PP4C playing an upstream role in which PP4C activity is needed to activate or maintain the activation of Aurora B or Plk1. Alternatively, PP4C could have indirect actions that affect a poorly characterized aspect of these
known pathways. Clearly future studies will be required to determine the molecular mechanisms by which the suppression of PP4C produces mitotic slippage and tetraploid cell death.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: B. Theobald, K. Bonness, R.E. Honkanen
Development of methodology: B. Theobald, K. Bonness, G. Urban, A. Huang, R.E. Honkanen
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): B. Theobald, K. Bonness, A. Musiyenko, G. Urban, A. Huang
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): B. Theobald, K. Bonness, A. Musiyenko, J.F. Andrews, G. Urban, A. Huang, R.E. Honkanen
Writing, review, and/or revision of the manuscript: B. Theobald, K. Bonness, N.M. Dean, R.E. Honkanen

References


Suppression of Ser/Thr Phosphatase 4 (PP4C/PPP4C) Mimics a Novel Post-Mitotic Action of Fostriezin, Producing Mitotic Slippage Followed by Tetraploid Cell Death

Benjamin Theobald, Kathy Bonness, Alla Musiyenko, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/1541-7786.MCR-13-0032

Supplementary Material
Access the most recent supplemental material at:
http://mcr.aacrjournals.org/content/suppl/2013/05/13/1541-7786.MCR-13-0032.DC1

Cited articles
This article cites 48 articles, 17 of which you can access for free at:
http://mcr.aacrjournals.org/content/11/8/845.full.html#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.